Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets

  • J. Capdevila
  • A. Meeker
  • R. Garcia-Carbonero
  • Kristian Pietras
  • A. Astudillo
  • O. Casanovas
  • A. Scarpa
Publishing year: 2014
Language: English
Pages: 345-351
Publication/Series: Cancer Metastasis Review
Volume: 33
Issue: 1
Document type: Journal article review
Publisher: Springer

Abstract english

Neuroendocrine tumors (NETs) represent a heterogeneous group of diseases with varied natural history and prognosis depending upon the organ of origin and grade of aggressiveness. The most widely used biomarker to determine disease burden and monitor response to treatment is chromogranin A (CgA), but it is far from being the optimal predictive and prognostic biomarker in NETs. Biological understanding and derived treatment options for NETs have changed markedly in recent years. Over the last decade, the genomic landscape of these tumors has been extensively investigated. This has resulted in the discovery of mutations and expression anomalies in genes and pathways such as the PI3K/Akt/mTOR, DAXX/ATRX, and MEN1, which are promising predictive and prognostic biomarkers and future candidates for targeted therapies. Additionally, the study of tumor stroma and environment are one of the most promising fields for discovery of potential new targets and biomarkers.


  • Cancer and Oncology
  • Neuroendocrine tumors
  • Biomarker
  • Chromogranin A


  • ISSN: 0167-7659
Kristian Pietras
E-mail: kristian [dot] pietras [at] med [dot] lu [dot] se


Division of Translational Cancer Research

+46 46 222 64 29

MV404 A31B1


Project manager

Experimental oncology